- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04969081
Impact of Work Activity on SUD Outcomes
September 3, 2026 updated by: VA Office of Research and Development
Augmenting Early Phase Substance Use Treatment With Therapeutic Work Activity to Improve Clinical Outcomes: a New Indication for an Old Intervention
To date, there are no studies of the therapeutic effects of varied work-focused programs in Veterans undergoing outpatient substance use disorder (SUD) treatment.
The investigators propose a randomized clinical trial to test the effects of work-focused programs on improving sobriety and other clinical outcomes in Veterans early in the course of recovery from SUD. Veterans will be randomized to either receive or not receive referral for work-focused therapeutic programs.
Primary aim is to examine effects of work-focused programs on sobriety outcomes, namely sobriety and global functioning.
Secondary aim is to examine effects of work-focused programs on psychiatric symptoms, self esteem/efficacy, and quality of life.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The investigators propose a trial to test the effects of Incentive Therapy (IT) and Other Therapeutic and Supported Employment Services (Other TSES) on improving SUD outcomes in newly recovering Veterans in outpatient treatment.
In line with eligibility criteria for different TSES programs, the investigators will employ a two branch study: One branch will be for Veterans who are not interested in pursuing competitive employment, and will be a two arm RCT with randomization (2:1) to referral for IT + treatment as usual (TAU; including usual SUD outpatient treatment) or TAU alone.
The second branch will be for Veterans who express interest in competitive employment, and will be a two arm Randomized Controlled Trial (RCT) with randomization (2:1) to referral for TSES competitive employment services + TAU or TAU alone.
Total Intent to Treat sample will be 140 (n=70 per branch).
Primary outcomes will be percent days abstinent during 3 month active phase and clinical global impression scale scores at 6 months.
Secondary outcome will be psychiatric symptoms, self esteem/efficacy and quality of life.
Study Type
Interventional
Enrollment (Actual)
103
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Connecticut
-
West Haven, Connecticut, United States, 06516-2770
- VA Connecticut Healthcare System West Haven Campus, West Haven, CT
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
14 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Participants will be Veterans enrolled in VACHS substance use treatment, who at time of consenting into the study are within 30 days of detoxification or last substance use as per medical record.
- Additional criteria will be as follows:
- Meeting DSM-V criteria for any current Substance Use Disorder (SUD) (e.g., opioids, cocaine, marijuana, amphetamine, or alcohol)
- Competent to give written informed consent and HIPAA authorization
Exclusion Criteria:
- Involvement in a legal case that may lead to incarceration during study period
- Developmental disability or medical illness that would prevent therapeutic work activity, as judged by PI or clinical staff providing this service
- Plans to relocate outside geographic area that would make follow-up unlikely
- And/or lack of willingness to provide contact information of someone who can help us contact the participant in the event that the investigators are unable to maintain contact directly
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: treatment as usual
usual substance use treatment
|
usual treatment
|
|
Experimental: treatment as usual plus referral to work focused program
usual substance use treatment plus referral to a competitive or non-competitive work-focused program
|
usual treatment
referral to Incentive Therapy or to Other Therapeutic and Supported Employment Services
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
percent days abstinent
Time Frame: 3 months
|
percent days abstinent during 3-month active phase
|
3 months
|
|
Clinical Global Impression
Time Frame: 6 months
|
Clinical Global Impression ratings conducted at 6 months from study entry.
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
change from baseline in BASIS-24
Time Frame: 3 months
|
change in Behavior and Symptom Identification Scale, self-report
|
3 months
|
|
change from baseline in Rosenberg self-esteem scale
Time Frame: 6 months
|
change in self report of self-esteem
|
6 months
|
|
change from baseline in New General Self-Efficacy Scale
Time Frame: 6 months
|
change in self-report of self-efficacy
|
6 months
|
|
change in WHOQOL BREF
Time Frame: 6 months
|
change in self-report of quality of life
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Joanna M. Fiszdon, PhD, VA Connecticut Healthcare System West Haven Campus, West Haven, CT
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 3, 2022
Primary Completion (Actual)
July 31, 2026
Study Completion (Actual)
August 10, 2026
Study Registration Dates
First Submitted
July 1, 2021
First Submitted That Met QC Criteria
July 19, 2021
First Posted (Actual)
July 20, 2021
Study Record Updates
Last Update Posted (Actual)
September 9, 2026
Last Update Submitted That Met QC Criteria
September 3, 2026
Last Verified
September 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- D3493-R
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
De-identified, anonymized dataset will be created.
This dataset may be shared with other investigators, upon written request, under a data use agreement prohibiting the recipient from identifying or re-de-identifying (or taking steps to identify or re-identify) any individual whose data are included in the dataset.
The data sharing agreement will also restrict redistribution to third parties and proper acknowledgment of the data source.
These datasets will be shared per guidelines provided by VACHS Information Security Officer.
IPD Sharing Time Frame
After study completion
IPD Sharing Access Criteria
After study completion for no less than 7 years.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.